NasdaqCM - Nasdaq Real Time Price USD

Unicycive Therapeutics, Inc. (UNCY)

0.6027
+0.0068
+(1.14%)
As of 1:14:42 PM EDT. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for UNCY

Recent News: UNCY

View More
Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire 5 days ago
Analysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before Long

Analysts Expect Breakeven For Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Before Long
Simply Wall St. 12 days ago
Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis

Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis
GlobeNewswire last month
Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
GlobeNewswire last month
Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire last month
Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia

Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia
GlobeNewswire 2 months ago
Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360

Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
GlobeNewswire 2 months ago
Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
GlobeNewswire 3 months ago
Here's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Situation

Here's Why We're Watching Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn Situation
Simply Wall St. 3 months ago
Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science
GlobeNewswire 4 months ago
Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics

Unicycive Therapeutics Announces Publication of Oxylanthanum Carbonate (OLC) Positive Bioequivalence Data in Clinical Therapeutics
GlobeNewswire 4 months ago
View More

Related Tickers

ELEV Elevation Oncology, Inc.
0.3275
+15.93%
 
PHRRF PharmaTher Holdings Ltd.
0.1450
0.00%
 
MIST Milestone Pharmaceuticals Inc.
1.3118
+7.54%
 
NUVB Nuvation Bio Inc.
2.3150
+2.43%
 
URGN UroGen Pharma Ltd.
8.08
+10.47%
 
ABEO Abeona Therapeutics Inc.
6.17
+1.15%
 
INAB IN8bio, Inc.
0.1246
-3.18%
 
XFOR X4 Pharmaceuticals, Inc.
2.8800
-1.37%
 
IRD Opus Genetics, Inc.
1.0200
0.00%
 
ARDX Ardelyx, Inc.
3.9250
+1.16%